Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091663
Status:
COMPLETED
Last Update Posted:
2014-03-04
First Post:
2004-09-15
Brief Title:
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer NSCLC
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Multicenter Open-Label Phase IIIb Trial of Tarceva Erlotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IIIb multicenter open-label trial of daily oral Tarceva in patients with advanced inoperable Stage IIIb or IV NSCLC who have progressed following standard chemotherapy treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None